Novocure Ltd Stock
Price
Target price
€11.02
€11.02
-1.040%
-0.115
-1.040%
-
16.12.25 / Tradegate
WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Novocure Ltd Stock
We can see a decrease in the price for Novocure Ltd. Compared to yesterday it has lost -€0.115 (-1.040%).
Our community identified positive and negative aspects for Novocure Ltd stock for the coming years. 1 users see the criterium "Shareholder structure" as a plus for the Novocure Ltd stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -1.040% | 0.732% | 13.114% | -63.539% | -62.174% | -84.302% | -91.458% |
| Ironwood Pharmaceuticals | -0.670% | -1.974% | 9.559% | -7.453% | -29.048% | -73.772% | -69.436% |
| Iovance Biotherapeutics Inc. | 5.750% | -1.471% | -11.031% | -74.482% | -72.450% | -68.779% | -94.954% |
| Alnylam Pharmace. | -0.360% | -6.779% | -13.894% | 43.510% | 47.322% | 54.038% | 193.268% |
News
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable
Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and